CNBC’s Jim Cramer on Monday emphasized his belief that GLP-1 drugs primarily used to treat diabetes and obesity and the companies that make them, like Eli...
CFOTO | Future Publishing | Getty Images As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming...
Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing...
Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). On Thursday, AstraZeneca said...
CNBC’s Jim Cramer on Friday laid out what to look for going into next week, highlighting earnings reports from several retail outfits as well as the...
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the answer is: “yes, but not to...
My top 10 things to watch Friday, Nov. 10 1. U.S. stocks edge up in premarket trading Friday, with S & P 500 futures rising 0.43%...
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo,...
Check out the companies making headlines in midday trading. Starbucks — Shares jumped more than 10% after the company posted an earnings and revenue beat in...
Spencer Platt | Getty Images S&P 500 futures inched higher Thursday morning as investors shifted focus from the Federal Reserve’s policy decision to the latest batch...